Form 1-A/A - Offering Statement [Regulation A]: [Amend]
SEC Accession No. 0001214659-20-002568
Filing Date
2020-03-12
Accepted
2020-03-12 15:24:05
Documents
15

Document Format Files

Seq Description Document Type Size
1 primary_doc.html 1-A/A  
1 primary_doc.xml 1-A/A 16742
3 partiiandiii.htm PART II AND III 1396516
4 EXHIBIT 1A-3.3 ex1a-3_3.htm EX1A-3 HLDRS RTS 95705
5 EXHIBIT 1A-4.1 ex1a-4_1.htm EX1A-4 SUBS AGMT 64545
6 EXHIBIT 1A-6.6 ex1a-6_6.htm EX1A-6 MAT CTRCT 19647
7 EXHIBIT 1A-6.9 ex1a-6_9.htm EX1A-6 MAT CTRCT 56555
8 EXHIBIT 1A-6.10 ex1a-6_10.htm EX1A-6 MAT CTRCT 68477
9 EXHIBIT 1A-11.1 ex1a11_1.htm EX1A-11 CONSENT 3287
10 GRAPHIC alzamend_footer.jpg GRAPHIC 14158
11 GRAPHIC alzamend_header.jpg GRAPHIC 18240
12 GRAPHIC alzamendlogo.jpg GRAPHIC 17195
13 GRAPHIC aultsig.jpg GRAPHIC 8291
14 GRAPHIC chart2.jpg GRAPHIC 177842
15 GRAPHIC ex6_head.jpg GRAPHIC 7737
16 GRAPHIC jackmansig.jpg GRAPHIC 11728
  Complete submission text file 0001214659-20-002568.txt   2074985
Mailing Address 3802 SPECTRUM BLVD, SUITE C112C TAMPA FL 33612
Business Address 3802 SPECTRUM BLVD, SUITE C112C TAMPA FL 33612 844-722-6333
Alzamend Neuro, Inc. (Filer) CIK: 0001677077 (see all company filings)

EIN.: 811822909 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 1-A/A | Act: 33 | File No.: 024-11124 | Film No.: 20708541
SIC: 2834 Pharmaceutical Preparations